Potentiation of C1 Inhibitor by Glycosaminoglycans: Dextran Sulfate Species Are Effective Inhibitors of in Vitro Complement Activation in Plasma

Journal of Immunology

Volumn 159, Issue 4, 1997, Pages 1953-1960

  Wuillemin, Walter A ^a,c   Te Velthuis, Henk ^a   Lubbers, Yvonne T P ^a   De Ruig, Cornelis P ^a   Eldering, Eric ^a   Hack, C Erik ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; DEXTRAN SULFATE;

ARTICLE; COMPLEMENT ACTIVATION; DRUG EFFECT; HEMOLYSIS; HUMAN;

COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; DEXTRAN SULFATE; HEMOLYSIS; HUMANS;

EID: 0031571319     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Müller-Eberhard, H. J., and R. D. Schreiber. 1980. Molecular biology and chemistry of the alternative pathway of complement. Adv. Immunol. 29:1.
2. Cooper, N. R. 1985. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. 37:151.
3. Müller-Eberhard, H. J. 1992. Complement. Chemistry and Pathways. In Inflammation: Basic Principles and Clinical Correlates. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press Ltd., New York, p. 33.
4. Schumaker, V. N., P. Zavodszky, and P. H. Poon. 1987. Activation of the first component of complement. Annu. Rev. Immunol. 5:21.
5. Ziccardi, R. J., and N. R. Cooper. 1976. Activation of C1r by proteolytic cleavage. J. Immunol. 116:504.
6. Polley, M. J., and H. J. Müller-Eberhard. 1968. The second component of human complement: its isolation, fragmentation by C′1 sterase and incorporation into C′3 convertase. J. Exp. Med. 128:533.
7. Kerr, M. A. 1980. The human complement system: assembly of the classical pathway C3 convertase. Biochem. J. 189:173.
8. Sim, R. B., G. J. Arlaud, and M. G. Colomb. 1979. C1 inhibitor dependent dissociation of human complement C1 bound to immune complexes. Biochem. J. 179:449.
9. Ziccardi, R. J., and N. R. Cooper. 1979. Active disassembly of the first complement component, C1, by C1 inactivator. J. Immunol. 123:788.
10. Fujita, T., I. Gigli, and V. Nussenzweig. 1978. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J. Exp. Med. 148:1044.
11. Gigli, I., T. Fujita, and V. Nussenzweig. 1979. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Science 6596.
12. Kjellen, L., and U. Lindahl. 1991. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60:443.
13. Poole, A. R. 1986. Proteoglycans in health and disease: structure and functions. J. Biochem. 236:1.
14. Rosenberg, R. D., H. U. Choi, A. R. Poole, K. Lewandowska, and L. A. Culp. 1986. Biological roles of dermatan sulfate proteoglycans. Ciba Found. Symp. 124:47.
15. Ausprunk, D. H., C. L. Boudreau, and D. A. Nelson. 1981. Proteoglycans in the microvasculature. I. Histochemical localization in microvessels of the rabbit eye. Am. J. Pathol. 103:353.
16. Ihrcke, N. S., L. E. Wrenshall, B. J. Lindman, and J. L. Platt. 1993. Role of heparan sulfate in immune system-blood vessel interactions. Immunol. Today 14:500.
17. Rent, R., R. Myhrman, B. A. Fiedel, and H. Gewurz. 1976. Potentiation of C1 esterase inhibitor activity by heparin. Clin. Exp. Immunol. 23:264.
18. Sim, R. B., G. J. Arlaud, and M. G. Colomb. 1980. Kinetics of reaction of human C1 inhibitor with the human complement system protease C1r and C1s. Biochim. Biophys. Acta 612:433.
19. Caughman, G. B., R. J. Boackle, and J. Vesely. 1982. A postulated mechanism for heparins potentiation of C1 inhibitor function. Mol. Immunol. 19:287.
20. Weiss, V., and J. Engel. 1983. Heparin-stimulated modification of C1 inhibitor by subcomponent C1s of human complement. Hoppe-Seyler's Z. Physiol. Chem. 364:295.
21. Nilsson, T., and B. Wiman. 1983. Kinetics of the reaction between human C1 esterase inhibitor and C1r or C1s. Eur. J. Biochem. 129:663.
22. Lennick, M., S. A. Brew, and K. C, Ingham. 1986. Kinetics of interaction of C1 inhibitor with complement C1s. Biochemistry 25:3890.
23. Hortin, G. L., and B. L. Trimpe. 1991. C1 inhibitor: different mechanisms of reaction with complement component C1 and C1s. Immunol. Invest. 20:75.
24. Raepple, E., H.-U. Hill, and M. Loos. 1976. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-I. Immunochemistry 13:251.
25. Loos, M., J. E. Volanakis, and R. M. Stroud. 1976. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-II. Immunochemistry 13:257.
26. Loos, M., J. E. Volanakis, and R. M. Stroud. 1976. Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement-III. Immunochemistry 13:789.
27. Strunk, R., and H. R. Colten. 1976. Inhibition of the enzymatic activity of the first component of complement (C1) by heparin. Clin. Immunol. Immunopathol 6:248.
28. Kazatchkine, M. D., D. T. Fearon, D. D. Metcalfe, R. D. Rosenberg, and K. F. Austen. 1981. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J. Clin. Invest. 67:223.
29. Almeda, S., R. D. Rosenberg, and D. H. Bing. 1983. The binding properties of human complement component C1q: interaction with mucopolysaccharides. J. Biol. Chem. 258:785.
30. Maillet, F., M. Petitou, J. Choay, and M. D. Kazatchkine. 1988. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. Mol. Immunol. 25:917.
31. Hack, C. E., J. Hannema, A. J. M. Eerenberg-Belmer, T. A. Out, and R. C. Aalberse. 1981. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J. Immunol. 127:1450.
32. Nuijens, I. H., C. C. M. Huijbregts, G. M. van Mierlo, and C. E. Hack. 1987. Inactivation of C1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C1 inhibitor. Immunology 61:387.
33. Eldering, E., C. C. M. Huijbrechts, Y. T. P. Lubbers, C. Longstaff, and C. E. Hack. 1992. Characterization of recombinant C1 inhibitor P1 variants. J. Biol. Chem. 267:7013.
34. Potempa, J., E. Korzus, and J. Travis. 1994. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269:15957.
35. Salvesen, G., and H. Nagase. 1989. Inhibition of proteolytic enzymes. In Proteolytic Enzymes, a Practical Approach. R. J. Beynon and J. S. Bond, eds. IRL Press at Oxford University Press, Oxford, p. 83.
36. Nuijens, J. H., A. J. Eerenberg-Belmer, C. C. Huijbregts, W. O. Schreuder, R. J. Felt-Bersma, J. J. Abbink, L. G. This, and C. E. Hack. 1989. Proteolytic inactivation of plasma C1 inhibitor in sepsis. J. Clin. Invest. 84:443.
37. Wolbink, G. J., J. Bollen, J. W. Baars, R. J. ten-Berge, A. J. Swaak, J. Paardekooper, and C. E. Hack. 1993. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 163:67.
38. Hinshaw, L. B., D. J. Brackett, L. T. Archer, B. K. Beller, and M. F. Wilson. 1983. Detection of the "hyperdynamic state" of sepsis in the baboon during lethal E. coli infusion. J. Trauma 23:361.
39. de Boer, J. P., A. A. Creasey, A. Chang, D. Roem, A. J. Eerenberg, C. E. Hack, and F. Taylor, Jr. 1993. Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect. Immun. 61:4293.
40. Thomas, H., F. Maillet, D. Letourneur, J. Jozefonvicz, E. Fischer, and M. D. Kazatchkine. 1996. Sulfonated dextran inhibits complement activation and complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol. Immunol. 33:643.
41. Weiler, J. M., R. E. Edens, R. J. Linhardt, and D. P. Kapelanski. 1992. Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148: 3210.
42. Friedrichs, G. S., K. S. Kilgore, P. J. Manley, M. R. Gralinski, and B. R. Lucchesi. 1994. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit heart. Circ. Res. 75:701.
43. Sahu, A., and M. K. Pangburn. 1993. Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol. 30:679.
44. Wuillemin, W. A., M. Minnema, J. C. M. Meijers, D. Roem, A. J. M. Eerenberg, J. H. Nuijens, H. ten Cate, and C. E. Hack. 1995. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1 inhibitor. Blood 85:1517.
45. Pixley, R. A., M. Schapira, and R. W. Colman. 1985. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260:1723.
46. Schapira, M., C. F. Scott, and R. W. Colman. 1982. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69:462.
47. Wuillemin, W. A., E. Eldering, F. Citarella, C. P. de Ruig, H. ten Cate, and C. E. Hack. 1996. Modulation of contact system proteases by glycosaminoglycans: selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271: 12911.
48. Frank, M. M. 1992. Detection of complement in relation to disease. J. Allergy Clin. Immunol. 89:641.
49. Moore, F., Jr. 1994. Therapeutic regulation of the complement system in acute injury states. Adv. Immunol. 56:267.
50. Guerrero, R., F. Velasco, M. Rodriguez, A. Lopez, R. Rojas, M. A. Alvarez, R. Villalba, V. Rubio, A. Torres, and D. del Castillo. 1993. Endotoxin-induced pulmonary dysfunction is prevented by C1 esterase inhibitor. J. Clin. Invest. 91:2754.
51. Buerke, M., T. Murohara, and A. M. Lefer. 1995. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91:393.
52. Hack, C. E., H. J. Voerman, B. Eisele, H. O. Keinecke, J. H. Nuijens, A. J. Eerenberg, A. Ogilvie, R. J. Strack van Schijndel, U. Delvos, and L. G. Thijs. 1992. C1 esterase inhibitor substitution in sepsis [letter]. Lancet 339:378.
53. Ecker, E. E., and P. Gross. 1929. Anticomplementary power of heparin. J. Infect. Dis. 44:250.
54. Lindahl, U., K. Lidholt, D. Spillmann, and L. Kjellen. 1994. More to "heparin" than anticoagulation. Thromb. Res. 75:1.
55. r of the activating polyanion. Biochem. J. 248:715.
56. Corretge, E., and J. M. Nigretto. 1990. Molecular weight-dependent contact activation of plasma induced by soluble polystyrene and dextran derivatives. Thromb. Res. 59:463.
57. Tazi, S., G. Tans, H. C. Hemker, and J. M. Nigretto. 1992. Autoactivation of human blood coagulation factor XH on dextran derivatives of different molecular weight. Thromb. Res. 67:665.
58. Dawes, J. 1988. Measurement of the affinities of heparin, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. Anal. Biochem. 174:177.
59. Oshima, G. 1989. The molecular-mass dependence of dextran sulfate enhancement of inactivation of thrombin and fibrinogen and on factor Xa neutralization by antithrombin III. Biol. Chem. Hoppe-Seyler 370:715.